Prof. Dr. Ahmet Bilici made statements about ‘agnostic’ treatment, referring to the latest developments in cancer treatment. Prof. Dr. Stating that more information has been learned about the genetic steps involved in the emergence of cancer in recent years, Bilici said, “Thanks to this, many exciting developments have been made in oncological treatments. Specifically, targeted therapies and immunotherapies that act on a specific genetic mutation, which we call an individual biomarker, have made significant progress in many types of cancer, especially lung cancer. In addition to all these, new biomarkers have been found in the last two years that allow an ‘agnostic’ more sensitive cancer treatment independent of tumor tissue, ”he said.
THE LAST POINT IN PERSONALIZED TREATMENTS
Stating that most of these new treatments are in the form of oral pills, Prof. Dr. Bilici continued as follows:
However, some of the immunotherapies administered intravenously proved their efficacy in certain types of biomarkers as tumor agnostic. First of all, it was shown that immunotherapy treatments were effective in cancer types with high microsatellite instability, missing DNA mismatch repair (dMMR), or high tumor mutation burden (TMB), regardless of the cancer type and the organ where it is located. Since then, research into new treatments targeting cancer agnostic biomarkers has also gained momentum. In adult and childhood cancers with another mutation known as NTRK (neurotrophic receptor tyrosine kinase) gene fusion, a targeted or smart drug called larotrectinib has been developed. This was perhaps the most advanced point reached in oncological treatments when we consider the personalized treatments we know of before. Thus, the first smart pill with demonstrated agnostic effectiveness was developed, regardless of where the organ where the cancer originated. “
“LOW SIDE EFFECTS”
Prof. Dr. Finally, Bilici said, “These developments also showed the necessity of performing genetic biomarker tests independent of the cancer type, which is more likely to be seen in certain tumors. On the other hand, like smart drugs that have been shown to be effective before, these newly developed drugs mostly affect cancerous cells, affecting normal cells at all or minimally. Thus, the success of the treatment increases more, and possible side effects are seen very rarely and the quality of life of the patients is not negatively affected. It seems that further development of ‘agnostic’ treatments independent of such tumor location in the future will enable us to make a more sensitive and more effective cancer treatment ”.